Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Objective This study aimed to assess the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) and Ultrasound (US) and its sub-classification system for distinguishing ovarian masses. Methods O-RADS US was used for the retrospective analysis of 606 ovarian masses of Chinese from two medical centers by two gynecologic sonographers with varying experience. The O-RADS 4 categories masses were further sub-classified into O-RADS 4a and O-RADS 4 b through three different approaches(O-RADS A1/A2/A3). Results The AUC of O-RADS US for differentiating benign from malignant ovarian masses was 0.927 (95% CI, 0.903—0.946, P < 0.001). The optimal cut-off value for predicting malignancy was>O-RADS 3, with sensitivity and specificity of 98.60% and 68.90%,respectively. The diagnostic efficacy of the three sub-classification systems surpassed that of O-RADS US(P < 0.05). Specifically, A2 approach(Within O-RADS 4 lesions, unilocular and multilocular cysts with solid components were sub-classified as O-RADS 4 b, whereas the remaining O-RADS 4 lesions were sub-classified as O-RADS 4a) resulted in an AUC of 0.942(95% CI, 0.921—0.960, P<0.001). The best cut-off value predicting malignancy was>O-RADS 4a, exhibiting relatively high specificity (82.51%) and maintaining a high sensitivity (93.01%). Conclusion The diagnostic efficacy of O-RADS US for identifying ovarian tumors is good, but specificity is slightly lower. This study enhanced diagnostic specificity after subclassifying O-RADS 4 lesions, especially A2 approach. It holds significant clinical value for Chinese women and merits further clinical promotion and application. Advances in knowledge The sub-classification of O-RADS US allow better identifying ovarian tumors, facilitating informed preoperative clinical management and diagnosis.
Objective This study aimed to assess the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) and Ultrasound (US) and its sub-classification system for distinguishing ovarian masses. Methods O-RADS US was used for the retrospective analysis of 606 ovarian masses of Chinese from two medical centers by two gynecologic sonographers with varying experience. The O-RADS 4 categories masses were further sub-classified into O-RADS 4a and O-RADS 4 b through three different approaches(O-RADS A1/A2/A3). Results The AUC of O-RADS US for differentiating benign from malignant ovarian masses was 0.927 (95% CI, 0.903—0.946, P < 0.001). The optimal cut-off value for predicting malignancy was>O-RADS 3, with sensitivity and specificity of 98.60% and 68.90%,respectively. The diagnostic efficacy of the three sub-classification systems surpassed that of O-RADS US(P < 0.05). Specifically, A2 approach(Within O-RADS 4 lesions, unilocular and multilocular cysts with solid components were sub-classified as O-RADS 4 b, whereas the remaining O-RADS 4 lesions were sub-classified as O-RADS 4a) resulted in an AUC of 0.942(95% CI, 0.921—0.960, P<0.001). The best cut-off value predicting malignancy was>O-RADS 4a, exhibiting relatively high specificity (82.51%) and maintaining a high sensitivity (93.01%). Conclusion The diagnostic efficacy of O-RADS US for identifying ovarian tumors is good, but specificity is slightly lower. This study enhanced diagnostic specificity after subclassifying O-RADS 4 lesions, especially A2 approach. It holds significant clinical value for Chinese women and merits further clinical promotion and application. Advances in knowledge The sub-classification of O-RADS US allow better identifying ovarian tumors, facilitating informed preoperative clinical management and diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.